← Patent-cliff monitor small molecule MOUNJARO (AUTOINJECTOR) TIRZEPATIDE
Loss of exclusivity December 2041 latest FDA-listed patent expiry
Company ELI LILLY AND CO
Drug detail Brand name MOUNJARO (AUTOINJECTOR) Active ingredient TIRZEPATIDE Strength 5MG/0.5ML (5MG/0.5ML) Dosage form SOLUTION Route SUBCUTANEOUS Modality Small molecule FDA approval May 2022 Marketing status RX
Listed patents Patent Expires Type 12295987 December 2041 use U-4192 12616740 July 2039 use U-4502 12343382 July 2039 use U-4400 12453756 June 2039 product 12453755 June 2039 use U-4378 12629404 June 2039 product 11357820 June 2039 product 9474780 May 2036 substance, product
Regulatory exclusivity Code Expires NPP December 2028 NCE May 2027
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.